References
- McCallum R W. Cisapride: a new class of prokinetic agent. Am J Gastroenterol 1991; 86: 135–49
- Nyrén O. Therapeutic trial in dyspepsia: its role in the primary care setting. Scand J Gastroenterol 1991; 26: 61–9, Suppl 182
- Rösch W. Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1989; 24: 54–8, Suppi 165
- Reyntjens A. Rationale for the development of a novel gastrointestinal prokinetic cisapride. Scand J Gastroenterol 1989; 24: 1–6, Suppl 165
- Talley N J, McNeil D, Piper D W. Discriminant value of dyspeptic symptoms: a study of the clinical presentation of 221 patients with dyspepsia of unknown cause, peptic ulceration, and cholelithiasis. Gut 1987; 28: 40–6
- Johnson A G. The effects of cisapride on antroduodenal coordination and gastric emptying. Scand J Gastroenterol 1989; 24: 36–43, Suppl 165
- Malagelada J-R. Gastrointestinal motor disturbances in functional dyspepsia. Scand J Gastroenterol 1991; 26: 29–32, Suppl 182
- Nyrén O. Secretory abnormalities in functional dyspepsia. Scand J Gastroenterol 1991; 26: 25–8, Suppl 182
- Talley N J. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991; 26: 47–60, Suppl 182
- Bianchi Porro G, Pace F, Caruso I. Why are nonsteroidal antiinflammatory drugs important in peptic ulceration?. Aliment Pharmacol Ther 1987; 1: 540S–7S
- Waldron B, Cullen P T, Kumar R. Evidence for hypo-motility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246–51
- Jian R, Ducrot F, Ruskone A. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. Dig Dis Sci 1989; 34: 657–64
- Toussaint J, Gossuin A, Deruyttere M. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991; 32: 1280–5
- Benson M J, Castillo F D, Deeks J. Assessment of the effect of cisapride on proximal small bowel motility by prolonged ambulatory manometry. Gastroenterology 1991; 100, Suppl:419